Please login to the form below

Not currently logged in
Email:
Password:

GSK unveils board and committee changes

Manvinder Singh Banga named as a non-executive director

edit-manvinder-singh-bangaGlaxoSmithKline has appointed Manvinder Singh (Vindi) Banga as a non-executive director, effective from September 1 of this year.

Banga will also succeed Sir Deryck Maughan as senior independent director from May 5 2016. Maughan will not seek re-election and will retire from the board.

Banga held numerous roles at Unilever over 23 years, including his most recent position as president of the global foods, home and personal care business as well as being a member of the firm's executive board.

Commenting on the appointment, Sir Philip Hampton, chairman designate at GSK, said: “I am delighted that Vindi is joining the board.

“Vindi brings with him many years of experience and a track record of delivering outstanding performance in a highly competitive global consumer-focused industry which will be invaluable to GSK. My colleagues and I very much look forward to welcoming him to the board.”

GSK additionally announced Urs Rohner, non-executive director, has been named as chairman of the remuneration committee and Lynn Elsenhans, also a non-executive director, has been appointed as chairman of the corporate responsibility committee, both effective from May 8 2015.

19th May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics